Pfs230D1-CRM197 + R21 + Matrix-M1

Pfs230D1-CRM197 + R21 + Matrix-M1 is a **multi-component malaria vaccine candidate** composed of three constituents: **Pfs230D1-CRM197**, a conjugate of the Pfs230 domain 1 (a sexual-stage malaria surface antigen from Plasmodium falciparum) chemically linked to CRM197 (a non-toxic mutant of diphtheria toxin serving as a carrier protein); **R21**, a next-generation subunit vaccine based on the fusion of Plasmodium falciparum circumsporozoite protein (CSP) with hepatitis B surface antigen (HBsAg), designed to elicit immune responses against the parasite's sporozoite stage; and **Matrix-M1**, a saponin-based adjuvant developed to boost immune responses. The combination simultaneously targets both the transmission (sexually developed) and pre-erythrocytic (sporozoite) stages of malaria, aiming to provide robust immunity that blocks infection and transmission. The main indication is the prevention of malaria, with current trials focusing on pediatric and adult populations in endemic regions[1][4][5][8].

Other names

Pfs230D1-CRM197 + R21 in Matrix-M1Matrix-M1-Serum Institute of India Pvt. Ltd.-malariaMatrix-M-1-Serum Institute of India Pvt. Ltd.-malariaMatrix-M 1-Serum Institute of India Pvt. Ltd.-malariaR21/Matrix-M1 + Pfs230D1-CRM197Pfs230D1-CRM197/R21/Matrix-M1